BioLight Life Sciences Ltd (BOLT) - Total Liabilities
Based on the latest financial reports, BioLight Life Sciences Ltd (BOLT) has total liabilities worth ILA2.24 Million ILA (≈ $6.01K USD) as of December 2025. Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities. See BOLT defensive interval ratio to measure how many days the company can operate on defensive assets alone.
BioLight Life Sciences Ltd - Total Liabilities Trend (2005–2025)
This chart illustrates how BioLight Life Sciences Ltd's total liabilities have evolved over time, based on quarterly financial data. Check BOLT asset liquidity ratio to evaluate the company's liquid asset resilience ratio.
BioLight Life Sciences Ltd Competitors by Total Liabilities
The table below lists competitors of BioLight Life Sciences Ltd ranked by their total liabilities.
| Company | Country | Total Liabilities |
|---|---|---|
|
Ambertech Ltd
AU:AMO
|
Australia | AU$30.93 Million |
|
Metal Bank Ltd
AU:MBK
|
Australia | AU$334.64K |
|
Exicure Inc
NASDAQ:XCUR
|
USA | $10.42 Million |
|
Streamplay Studio Ltd
AU:SP8
|
Australia | AU$7.18 Million |
|
Bank Danamon Indonesia Tbk
JK:BDMN
|
Indonesia | Rp239.90 Trillion |
|
Churchill Resources Inc
V:CRI
|
Canada | CA$1.26 Million |
|
Celsius Resources Limited
F:FX8
|
Germany | €1.07 Million |
|
Trellidor Holdings Ltd
JSE:TRL
|
South Africa | ZAC104.77 Million |
Liability Composition Analysis (2005–2025)
This chart breaks down BioLight Life Sciences Ltd's total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted. For the complete balance sheet picture, see BioLight Life Sciences Ltd asset portfolio.
Liquidity & Leverage Metrics
Key Metrics Explained
| Metric | Value | Description |
|---|---|---|
| Current Ratio | 12.19 | Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities) |
| Quick Ratio | N/A | More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities) |
| Cash Ratio | N/A | Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities) |
| Debt to Equity | 0.07 | Measures financial leverage (Total Liabilities ÷ Shareholder Equity) |
| Debt to Assets | 0.05 | Portion of assets financed with debt (Total Liabilities ÷ Total Assets) |
Liability Trends Comparison
This chart compares key liability metrics across different time periods, showing how BioLight Life Sciences Ltd's debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.
Annual Total Liabilities for BioLight Life Sciences Ltd (2005–2025)
The table below shows the annual total liabilities of BioLight Life Sciences Ltd from 2005 to 2025.
| Year | Total Liabilities | Change |
|---|---|---|
| 2025-12-31 | ILA2.24 Million ≈ $6.01K |
-33.64% |
| 2024-12-31 | ILA3.38 Million ≈ $9.06K |
+7.27% |
| 2023-12-31 | ILA3.15 Million ≈ $8.45K |
-5.06% |
| 2022-12-31 | ILA3.32 Million ≈ $8.90K |
+20.52% |
| 2021-12-31 | ILA2.75 Million ≈ $7.38K |
-41.68% |
| 2020-12-31 | ILA4.72 Million ≈ $12.66K |
-30.60% |
| 2019-12-31 | ILA6.80 Million ≈ $18.24K |
-45.51% |
| 2018-12-31 | ILA12.49 Million ≈ $33.47K |
-25.38% |
| 2017-12-31 | ILA16.73 Million ≈ $44.86K |
-11.48% |
| 2016-12-31 | ILA18.90 Million ≈ $50.68K |
+16.61% |
| 2015-12-31 | ILA16.21 Million ≈ $43.46K |
+10.30% |
| 2014-12-31 | ILA14.70 Million ≈ $39.40K |
+20.23% |
| 2013-12-31 | ILA12.22 Million ≈ $32.77K |
+168.46% |
| 2012-12-31 | ILA4.55 Million ≈ $12.21K |
-25.18% |
| 2011-12-31 | ILA6.08 Million ≈ $16.31K |
-17.96% |
| 2010-12-31 | ILA7.42 Million ≈ $19.88K |
-19.22% |
| 2009-12-31 | ILA9.18 Million ≈ $24.62K |
-77.13% |
| 2006-12-31 | ILA40.15 Million ≈ $107.65K |
+1393.27% |
| 2005-12-31 | ILA2.69 Million ≈ $7.21K |
-- |
About BioLight Life Sciences Ltd
BioLight Life Sciences Ltd. engages in the investment, development, management, and commercialization of products in the fields of advanced medical devices, pharmaceuticals, diagnostics, and digital medicine in Israel. The company offers TeaRx, a diagnostic platform intended for point-of-care testing of ophthalmic pathologies through multi-parameter composition analysis of the tear fluid; TeaRx D… Read more